XORTX Therapeutics Inc. is a biotechnology company with three drug development programs, two of which are clinically advanced products under development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products – XRx-008 and XRx-101 - that target xanthine oxidase to inhibit production of uric acid. The Company has a growing portfolio of intellectual property and in some cases claims within granted patents has established proof of concept through independent clinical studies.
XORTX’s pipeline includes proprietary and novel product candidates currently in clinical development:
XRx-008 is being developed as a treatment of progressive kidney disease in Autosomal Dominant Polycystic Kidney Disease (ADPKD).
XRx-101 to treat acute kidney injury as well as health consequences associated with Coronavirus / COVID-19 infection.
XORTX has received an important endorsement of its programs from the PKD Foundation (www.pkdcure.org) and is collaborating with the foundation. This collaboration will help advance XORTX’s programs to define the beneficial effects of XORTX’s therapies, in ADPKD patients and potentially other forms of polycystic kidney disease as well. XORTX believes that there are substantial benefits to working with the leading polycystic kidney disease foundation in the world and that this collaboration on the development of treatments could redefine how physicians treat this disease in the future.
At XORTX, we are dedicated to advancing treatments that improve the care and quality of life of patients suffering from life-threatening diseases.